Dear customer, we would like to introduce our new products and hope you will find them interesting. Below is a list of events, in which we plan to participate in 2016:

- **2nd Symposium Tumor Metabolism meets Immunology** (28 \ 04 \ 2016 - 30 \ 04 \ 2016 - Regensburg)
- **Analytica 2016** (10 \ 05 \ 2016 - 13 \ 05 \ 2016 - Munich)
- **AAI 2016** (13 \ 05 \ 2016 - 17 \ 05 \ 2016 - Seattle)
- **D.A.CH-Tag der DGE, ÖGES und SGED** (16 \ 05 \ 2016 - 28 \ 05 \ 2016 - Munich)
- **BIO International Convention** (06 \ 06 \ 2016 - 09 \ 06 \ 2016 - San Francisco)
- **19th Meeting on T-Cells – Subsets and functions** (27 \ 06 \ 2016 - 28 \ 06 \ 2016 - Marburg)
- **46th Annual Meeting German Society of Immunology (DGfI)** (27 \ 09 \ 2016 - 30 \ 09 \ 2016 - Hamburg)
- **6. Jahrestagung der ÖGLMKC** (08 \ 11 \ 2016 - 11 \ 11 \ 2016 - Salzburg)
- **20th Joint-Meeting “Signal Transfuction: Receptors, Mediators and Genes”** (09 \ 11 \ 2016 - 11 \ 11 \ 2016 - Weimar)
- **MEDICA 2016** (14 \ 11 \ 2016 - 17 \ 11 \ 2016 - Dusseldorf)
- **8th Nachwuchswissenschaftler-Meeting – Biochemische Pharmakologie und Toxikologie (GBM)** (02 \ 12 \ 2016 - 03 \ 12 \ 2016 - Günzburg)

**FEATURED PRODUCT: HUMAN AMINOACYLASE-1 ELISA**

Aminoacylase-1 (ACY-1) is a potential biomarker of **long-term outcome after kidney transplantation**. Serum ACY-1 concentration was **high** in patients with **tubular cell damage**. ACY-1 expression is also significantly **correlated** with serum alpha fetoprotein level and **tumor invasiveness**.

- Validated for human serum, plasma (heparin, citrate) and urine samples
- **High sensitivity** (LOD 0.14 ng/ml)
- Short assay protocol
- All test procedures are performed at room temperature

Aminoacylase-1 catalyzes the hydrolysis of N-acetylated amino acids into the free amino acid and acetic acid. ACY-1 plays a general role in the cytosolic breakdown of acetylated amino acids generated during intracellular protein degradation.

In **kidney transplantation**, serum ACY-1 levels were increased significantly in the majority of patients with delayed graft function (DGF), but rose in only a minority of patients with immediate function. This showed the potential clinical utility of serum ACY-1 levels immediately post kidney transplantation, enabling **subdivision of patients with delayed graft function in terms of long-term outcome**. Serum ACY-1 concentration was high in patients with **tubular cell damage** due to ischemia-reperfusion injury (IRI) and/or acute tubular necrosis.

ACY-1 also interacts with sphingosine kinase type 1, which is involved in promoting cell growth and inhibiting apoptosis of tumor cells. ACY-1 plays a role in **regulating responses** of the cell to **oxidative stress**. ACY-1 serves as a putative **suppressor** in renal cell carcinoma, hepatocellular carcinoma and small cell lung cancer.

An enzymatic deficiency in ACY-1 may result in **defects in brain metabolism and function**, such as encephalopathy, unspecific psychomotor delay, psychomotor delay with atrophy of the vermis and syringomyelia, marked muscular hypotonia or normal clinical features (e.g. fever). **Epileptic seizures** are a frequent feature in these patients. ACY-1 deficiency has also been described as an **inborn error of metabolism** identified in children who have increased urinary excretion of N-acetylamino acids.

**RELATED PRODUCTS**

RD172406100  Aminoacylase-1 Human E. coli
**FEATURED PRODUCT: HUMAN OXIDIZED LOW-DENSITY LIPOPROTEIN RECEPTOR 1 HEK293**

Oxidized low-density lipoprotein receptor 1 (LOX1) belongs to the C-type lectin superfamily. The gene is regulated through the cyclic AMP signaling pathway. Mutations of this gene have been associated with atherosclerosis, risk of myocardial infarction, and may modify the risk of Alzheimer's disease. Alternate splicing results in multiple transcript variants.

LOX-1 as a scavenger receptor binds, internalizes and degrades oxidized low-density lipoprotein. This protein may also be involved in the regulation of Fas-induced apoptosis. LOX-1 is a homodimer with a reactive backbone that can bind to a host of different ligands, including small molecules, and whole cells. LOX-1 is involved in many intercellular, intracellular, and molecular processes that are atherogenic. LOX-1 levels are elevated within atherosclerotic plaques and its expression is induced by proinflammatory cytokines. It is a likely vascular disease biomarker as well as an ideal choice for drug therapy aimed at preventing cardiovascular disease.

BioVendor produces the recombinant Human Oxidized low-density lipoprotein receptor 1 in HEK293 cell line. The monomer of the protein contains 221 AA. MW: 25.3 kDa (calculated). Endotoxin-free. UniProtKB acc. No. P78380 (Ser61–Gln273). N-terminal flag-tag

**Oxidized low-density lipoprotein receptor 1 Human HEK293**

**12 % SDS-PAGE separation of Human sLOX1 (Flag tag):**

1. M.W. marker – 14, 21, 31, 45, 66, 97 kDa
2. Reduced and boiled sample, 2.5 μg/lane
3. Non-reduced and non-boiled sample, 2.5 μg/lane
<table>
<thead>
<tr>
<th>CAT. NO.</th>
<th>NAME</th>
<th>SIZE</th>
<th>SOURCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>RD172475100</td>
<td>Human mu-Crystallin</td>
<td>0.1 mg</td>
<td>E. coli</td>
</tr>
<tr>
<td>RENT001010</td>
<td>Human Stable Fibroblast Growth Factor 2</td>
<td>0.01 mg</td>
<td>E. coli</td>
</tr>
<tr>
<td>RENT001050</td>
<td>Human Stable Fibroblast Growth Factor 2</td>
<td>0.05 mg</td>
<td>E. coli</td>
</tr>
<tr>
<td>RENT0011000</td>
<td>Human Stable Fibroblast Growth Factor 2</td>
<td>1 mg</td>
<td>E. coli</td>
</tr>
<tr>
<td>RD172470100</td>
<td>Human Myosin-binding protein C cardiac-type</td>
<td>0.1 mg</td>
<td>E. coli</td>
</tr>
<tr>
<td>RD172143100</td>
<td>Human Oxidized low-density lipoprotein receptor 1</td>
<td>0.1 mg</td>
<td>HEK293</td>
</tr>
<tr>
<td>RD172490100</td>
<td>Human Profilin-1</td>
<td>0.1 mg</td>
<td>E. coli</td>
</tr>
</tbody>
</table>